Aurinia Pharmaceuticals Inc. reported total revenue of $83.2 million for the quarter ending June 30, 2026, a 19% increase year-over-year. This growth, driven by strong sales of LUPKYNIS, reinforces investor confidence as the company aims for full-year revenue guidance of $315 million to $325 million.

Key Highlights

  • Specifically, net product sales totaled $153.0 million, reflecting a similar 21% rise for the half-year.
  • Aurinia's net income for the second quarter surged to $37.4 million, up 74% from $21.5 million in the same period of 2025.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) achieved total revenue of $83.2 million for the quarter ended June 30, 2026, reflecting a 19% increase compared to $70.0 million in the same period last year. Net product sales of LUPKYNIS, the company's FDA-approved therapy for lupus nephritis, contributed significantly, bringing in $79.4 million, also up 19% from the previous year. In the prior quarter, AUPH reported earnings per share (EPS) of $0.25, surpassing the $0.20 consensus estimate, signaling effective management and strong market demand.

This growth can help the company gain traction amid market pressures, particularly as overall shares have seen a decline of 1.0% year-to-date.

Revenue Highlights

Specifically, net product sales totaled $153.0 million, reflecting a similar 21% rise for the half-year. Revenue from licenses, collaborations, and royalties increased by 12% to $3.8 million for the quarter compared to $3.4 million in the prior year. Aurinia's numbers indicate a steady upward trend, closely aligning with its revenue guidance, which anticipates total revenue between $315 million and $325 million for 2026, a testament to its growth trajectory despite current market challenges.

Strong Profitability Growth

Aurinia's net income for the second quarter surged to $37.4 million, up 74% from $21.5 million in the same period of 2025. The company's diluted earnings per share reflected a significant increase to $0.28, compared to $0.16 in the prior year. For the first half of 2026, net income reached $71.8 million, a 60% rise compared to $44.9 million in the previous year.

This strong growth in net income underscores Aurinia's effective cost management and operational efficiencies, further enhancing investor appeal as the company continues to expand its product offerings and clinical development initiatives.

Future Clinical Developments

Aurinia remains focused on advancing its clinical pipeline, recently initiating the PRESERVE study, which will evaluate the combined efficacy of LUPKYNIS with various biologic agents in treating lupus nephritis. This multicenter trial plans to enroll around 150 patients across 50 sites in the U.S. The primary endpoint is to assess the proportion of patients achieving a complete renal response at six months. With growing cash reserves reported at $443.1 million as of June 30, 2026, the company is well-positioned to support its clinical and commercial progress.

Investors will be keenly watching for updates from this trial as well as the next earnings report for insights into the company's ongoing growth.

Peers Moving on This News

  • Arbutus Biopharma Corp (ABUS) down 0.6%
  • Zymeworks Inc (ZYME) down 0.4%

Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.